2.  A platform to address most causal mechanisms of disease  Drug the genome (DNA or RNA) with allele selectivity  NeuBase ’ s lead indications under development are Huntington ’ s disease (NT0100) and myotonic dystrophy (NT0200), both are billion - dollar peak sales opportunities  Stable against degradation with enhanced biodistribution  The modular design lends the ability to address a wide range of rare, genetic diseases and can be utilized for DNA therapeutic techniques, such as gene editing and gene regulation, as well as liquid biopsy testing Strong IP Portfo l io ♦ NeuBase holds an exclusive license to the PATrOL™ technology, with nine patents and applications covering matter and field of use of the platform ♦ Earliest patents have 2037 expiration, not including “Hatch Waxman” extensions ♦ Technology originally developed at Carnegie Mellon University Re c ent News  Demonstrates functional rescue in Myotonic Dystrophy type 1 model and allele – selective inhibition of KRAS mutations to inhibit Tumor growth  Reports financial results for second quarter of fiscal year 2021  Gerald J. McDougall appointed to Board of Directors  NBSE appoints Dr. Sandra Rojas - Caro as CMO  NBSE appoints Dr. Kia Motesharei Chief Business and Strategy Officer Management Dietrich A. Stepha n, Ph.D.—Chairma n & Chief Executive Officer , Founder Dr . Steph an i s an industr y veter an wh o is consider ed on e o f th e father s o f th e f ield o f precisio n medicin e, havin g train ed wit h the leadersh ip o f th e Huma n Genom e Project at th e NI H an d th en goin g o n to lead discover y resear ch at th e Translation al Genomics Resear ch Institu te an d serv e a s professo r an d chairm an o f th e Department o f Huma n Gene tics at th e Universit y o f Pittsburgh. Steph an has identif ied th e molecu lar b asis o f dozen s o f gene tic diseases an d publish ed extensivel y in journal s su ch a s Scienc e, the Ne w Englan d Journ al o f Medicin e, Natur e Genetics , PNA S, an d C ell. I n par allel, Dr . Steph an ha s found ed o r co-found ed 14 biotechnolog y companies an d has advis ed an addition al 1 2 compan ies. Th ese companies ar e back ed b y top- tier investor s suc h as Sequo ia Cap ital, KPCB , Th iel Cap ital, an d Khos la Ventur es as well a s corpor ate partner s su ch a s Lif e Technolog ies, Pfizer , an d Mayo Clinic. Sandra Rojas-Caro, M.D.---Chief Medical Officer Dr. Rojas-Caro has broad R&D leadership, executive management and team-building experience in private and public biotech companies and large pharma. She has been directly involved in successful global regulatory submissions, including an FDA and EMA approval and more than 10 investigational new drug (IND) applications. Most recently, she was Chief Medical Officer for Gemini Therapeutics, a company focused on redefining age-related macular degeneration (AMD) and linked disorders with precision medicine. At Gemini, she led development through several milestones, including the company’s first IND and the first cohorts of genetically selected patients dosed with the company’s leading biologic therapeutic. Sam Backenroth—Chief Financial Officer and SVP of Business Development Mr. Backenroth has extensive executive experience in financing and building biotechnology companies and most recently comes from Ohr Pharmaceutical. While at Ohr Pharmaceutical, he was instrumental in the company ’s growth from startup to a market capitalization of several hundred million and in moving a product from preclinical into late -stage clinical development. He previously worked as an investment banker with The Benchmark Company LLC, an investment banking firm specializing in micro - cap biotechnology transactions. While at Benchmark, Sam helped numerous small biotechnology companies raise equity growth capital through a variety of structures. Mr. Backenroth also acted as an advisor to multiple public and private biotechnology an d pharmaceutical companies in assisting with business development activities, joint ventures, licensing, strategic partnerships, a nd mergers & acquisitions. Robert Friedlander, M.D., M.A.---Chair, Scientific Advisory Board Dr. Friedlander is a renowned neurologist. Prior to NeuBase, he became the fourth Chairman of the Department of Neurological Surgeons at the University of Pittsburgh School of Medicine and the University of Pittsburgh Medical Center. Prior to joining the department, Dr. Friedlander was professor of neurosurgery at Harvard Medical School and vice-chairman of neurosurgery and associate director of cerebrovascular surgery at Brigham and Women’s Hospital in Boston. Presently, Dr. Friedlander is the Walter E. Dandy Professor of Neurosurgery, Neurology and Neurobiology, and Co-Director of the UPMC Neurological Institute. His work has been published in many top tier journals including Nature, Science, Nature Medicine, Nature Neuroscience and PNAS, and he has been recognized through many academic awards. In 2006, he was elected as a member of the prestigious American Society for Clinical Investigation. Dr. Friedlander is one of only three neurosurgeons elected as a member of the American Association of Physicians, and in 2018, he was elected to the National Academy of Medicine

3. Disclaimer Notice: The information contained in this e - mail message and its attachments is intended solely for the use of the indi- vidual(s) to whom it is addressed and may contain information that is the confidential information of Acorn Management Partners L.L.C. ("AMP") and its subsidiaries. The Information may be about companies in which A.M.P has or may receive compensation in the future. Any material in this message should be considered as ADVERTISMENT ONLY . Please consult with a certified finan- cial advisor before making any investment decisions. All information on this report should be confirmed before making an inve st- ment decision. Acorn Management Partners L.L.C. ("AMP") and its subsidiaries, and any affiliates and information providers m ake no implied or express warranties on the information provided. This is not to be construed as a solicitation to buy or sell se cur ities. As with any stock, the featured companies involve a high degree of risk and volatility, and all investors/advisors should know t hat they may lose a portion or all of their investment if they decide to purchase any stock. Acorn Management Partners L.L.C. ("AMP") , i ts affiliates, associates, relatives and anyone associated with in any manner reserves the right to either buy or sell shares in th e profiled company's stock. The Securities and Exchange Commission has compiled an extensive amount of information concerning investing, including the inherent risks involved. We encourage our readers to visit the SEC's website to acquire this important information. Safe Harb or Dis- closure: Acorn Management Partners L.L.C. ("AMP") website publications may contain or incorporate by reference "forward - looking statements, including certain information with respect to plans and strategies of the featured company. As such, any sta te- ments contained herein or incorporated herein by reference that are not statements of historical fact may be deemed to be for war d - looking statements. Without limiting the forgoing, the words "believe(s)," "anticipate(s)," "plan(s)," "expect(s)," "project( s)" and similar expressions are intended to identify forward - looking statements. There are a number of important factors that could caus e actual events or actual results of the Companies profiled herein to differ materially from these indicated by such forward - looki ng statements. Certain statements contained herein constitute forward - looking statements within the meaning of Section 27A of the S e- curities Act of 1933 and 21E of the Exchange Act of 1934. Such statements include, without limitation, statements regarding b usi- ness and financing, business trends, future operating revenues and expenses. Although the Company believes that the statement s a re reasonable, it can give no assurances that such expectations will prove to be correct. Investors are cautioned that any forwa rd looking statements made by the Company, or contained in any and/or all profile/research reports, contain no guarantee of future perfo rma nce, and that the actual result may differ materially from those set forth in the forward - looking statements. Difference in results c an be caused by various factors including, but not limited to, the Company's ability to be able to successfully complete planned fu ndi ng agreements, to successfully market its products in competitive industries or to effectively implement its business plan or st rat egies. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, ob jec tives, goals, assumptions, or future events or performance are not statements of historical fact and may be "forward looking stateme nts ." Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that inv olv e a number of risks and uncertainties which could cause actual results or events to differ materially from those presently antici pat ed. Forward looking statements in this action may be identified through the use of words such as "expects," "will," "anticipates, " "estimates," "believes," "may," or by statements indicating certain actions "may," "could," or "might" occur. We encourage ou r r ead- ers to invest carefully and review all forms of investments and read the investor information. More information please visit htt p:// www.sec.gov and/or (FINRA) at: http://www.FINRA.com. Readers can review all public filings by companies at the SEC's EDGAR page. The FINRA has published information on how to invest carefully at its web site. “ Full Market Awareness ” A Professional Relations Company And Consulting Firm 941 - 208 - 3919 Contact: Sean McDonald SMcDonald@AcornManagementPartners.com Atlanta, Georgia Sarasota, Florida

1. A CORN M ANAGEMENT P ARTNERS , LLC Biotechnology “ CNS ” Disease/Genetic For More Information “ Call AMP ” Robert Wheeler 941 - 208 - 3919 neubasetherapeutics.com NeuBase Therapeutics, Inc. (NCM: NBSE) is a biotechnology company developing its modular Peptide - nucleic acid AnTisense OL igonucleotide (PATrOL ™) platform to address genetic diseases. Drugging the genome to increase, decrease, or edit protein function to address base causality in disease. NeuBase intends to use its platform to address repeat expansion disorders, with an initial focus on Huntington ’ s disease and myotonic dystrophy, as well as a variety of other genetic disorders. Company Overview Platform Technology—PATrOL ™  The PATrOL ™ platform enables rapid drug design, blood - brain barrier penetration, broad systemic distribution for multi - tissue disease, increased cell permeability, and accessing of secondary RNA structures offering major advantages over all other ASO companies.  Pre - clinically, the PATrOL ™ platform has shown no immune response (negative side effects).  NeuBase is the first and only company to successfully create bifacial Janus bases, engineered nucleic acids that target double - stranded DNA or RNA by engaging both strands at once.  NeuBase recently won The Scientist ’ s Top 10 Innovations of 2019 Award for its Janus Base Technology.  The advantages of the platform enable the company to cohesively develop therapies for a wide range of rare genetic diseases, including repeat expansion disorders, dominant and recessive genetic disorders, and cancers driven by specific oncogenic mutations. Development Pipeline : Market Opportunity ♦ Global unmet need with orphan indications ♦ Competitors trade at significant valuations (in excess of ~$300 - $500M+) which include : Stoke Therapeutics (NGS: STOK, $737M) and Wave Life Sciences (NSD: WVE, 793M). Other clinical competitors trade in excess of $8B which include Ionis (NGS: IONS, $9.6B) and Alnylam (NGS: ALNY, $8B) AMP Quick Facts NeuBase Therapeutics (NCM:NBSE) August 2 0 2 1 NASDAQ : NBSE Price: $ 3.75 8 / 02 /21 Fiscal Yr: 9/30 Market Cap: $ 118.11 Cash on Hand: $ 24.2 M Insider Ownership: ~ 8.33 % Institutional Ownership: 25 % Potential Market Size: 20B+ Shares Out: 32.7 2 m Float: 28.7m Avg. Volume: 286.326k